Are AI and Algorithms Ushering in a New Age of Art?

Whether you’re an integrator, a designer or simply a label-defying creative, the experience is everything. Host Bryan Meszaros explores the story behind the exhibit to understand how a carefully crafted experience traps into the human experience to connect people to place.

 

Life offers up a lot of experience. As technology advances, a lot of our unique experiences come in the digital space. This is no different for Dutch artist Jeroen Van Der Most, whose work incorporates data, algorithms, and artificial intelligence.

On this episode of Experience By Design, Host Bryan Meszaros talks with Van Der Most about his art and how it crosses the divide between the digital world and the illusory boundary of our own. While a significant amount of his work is autonomous, he does commission work for organizations such as Amnesty International.

Meszaros and Van Der Most talked about the use of AI in Van Der Most’s work. He still explores textbooks and digs into what is out there in the digital world. He worked in data science, so being in the world of algorithms came naturally.

“I studied how people were having conversations online,” Van Der Most said. He would study the conversations online for brands. This work proved monotonous, so he started digging into creative outlets. He created basic Twitter images from the Tweets he used in his research. Doing this, he made portraits from the messages.

cAround 2013-14, new AI systems and learning appeared and took things to a new level. This allowed artists to engage on a deeper basis with new sounds and imagery. It also started raising some questions for Van Der Most.

“Along the way, I got more interested in the philosophical underlying of what AI is,” Van Der said. “It raises all sorts of philosophical questions.”

An example would be Van Gogh or Rembrandt. AI was used to study all of their work, and then it created new paintings. This raises all sorts of questions about what is creative, what does that mean for artists and humans.

Meszaros explores these subjects and more with Van Der Most.

Join host Bryan Meszaros on Experience by Design every other Wednesday as he explores the latest trends and solutions, helping craft the world’s most intriguing experiences.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More